title: Response of emotional unawareness after stroke to antidepressant treatment.
abstract: OBJECTIVE
  Unawareness of impairment (anosognosia) is a phenomenon associated with right hemisphere lesions. Unawareness of emotion has rarely been studied.
  
  
  METHODS
  Patients (N = 50) with poststroke major depression were administered the Toronto, Ontario, Canada, Alexithymia Scale to assess impairment in identifying feelings (F1), describing feelings (F2), and externally oriented thinking (F3). After eight weeks of treatment with sertraline or fluoxetine, patients were reassessed.
  
  
  RESULTS
  Alexithymia was significantly associated with right hemisphere lesions. Patients with alexithymia had a significant improvement in identifying and describing feelings, but not in externally oriented thinking. In addition, cognitive functions improved after antidepressant treatment in patients without alexithymia with left lesions only. On the contrary, functional activities of daily living and depressive symptoms improved both in patients with alexithymia and those without alexithymia.
  
  
  CONCLUSIONS
  The unawareness of emotions is a common impairment after right hemisphere stroke. This disorder may be significantly improved by antidepressant treatment.
authors.affiliation: IRCCS Fondazione Santa Lucia, Rome, Italy.
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Spalletta
authors.forename: Alessandra
authors.initials: A
authors.lastname: Ripa
authors.forename: Pietro
authors.initials: P
authors.lastname: Bria
authors.forename: Carlo
authors.initials: C
authors.lastname: Caltagirone
authors.forename: Robert G
authors.initials: RG
authors.lastname: Robinson
mesh_terms: D000203:Activities of Daily Living / Q000145:classification / Q000523:psychology; D000342:Affective Symptoms / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D000368:Aged; D000377:Agnosia / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001364:Awareness / Q000187:drug effects* / Q000502:physiology; D003071:Cognition / Q000187:drug effects / Q000502:physiology; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D004644:Emotions / Q000187:drug effects* / Q000502:physiology; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007389:Internal-External Control; D008609:Mental Status Schedule; D010555:Personality Inventory; D020280:Sertraline / Q000009:adverse effects / Q000627:therapeutic use*; D020521:Stroke / Q000150:complications* / Q000503:physiopathology / Q000523:psychology
chemical_list: D000928:Antidepressive Agents; D005473:Fluoxetine; D020280:Sertraline